204 related articles for article (PubMed ID: 36028583)
1. A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
Jin Y; Li R; Lin S; Jia J; Yang Y; Zhang D; He G; Li J
Ann Hematol; 2022 Nov; 101(11):2413-2419. PubMed ID: 36028583
[TBL] [Abstract][Full Text] [Related]
2. Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
Huang LF; Li L; Jia JS; Yang Y; Lin SY; Meng FK; Zhang DH; He GS
Transplant Cell Ther; 2022 Sep; 28(9):586.e1-586.e7. PubMed ID: 35609866
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag in children with severe aplastic anemia.
Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
Groarke EM; Patel BA; Gutierrez-Rodrigues F; Rios O; Lotter J; Baldoni D; St Pierre A; Shalhoub R; Wu CO; Townsley DM; Young NS
Br J Haematol; 2021 Feb; 192(3):605-614. PubMed ID: 33410523
[TBL] [Abstract][Full Text] [Related]
5. Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world.
Li R; Wang N; Chai X; Yang L; Liu K; He H; Lin S; Yang Y; Jia J; Zhang D; Gong Y; Shi J; He G; Li J
Clin Exp Med; 2023 Oct; 23(6):2619-2627. PubMed ID: 36645546
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; Kulasekararaj A; Iacobelli S; Terwel SR; Cook R; Griffin M; Halkes CJM; Recher C; Barraco F; Forcade E; Vallejo JC; Drexler B; Mear JB; Smith AE; Angelucci E; Raymakers RAP; de Groot MR; Daguindau E; Nur E; Barcellini W; Russell NH; Terriou L; Iori AP; La Rocca U; Sureda A; Sánchez-Ortega I; Xicoy B; Jarque I; Cavenagh J; Sicre de Fontbrune F; Marotta S; Munir T; Tjon JML; Tavitian S; Praire A; Clement L; Rabian F; Marano L; Hill A; Palmisani E; Muus P; Cacace F; Frieri C; van Lint MT; Passweg JR; Marsh JCW; Socié G; Mufti GJ; Dufour C; Risitano AM;
N Engl J Med; 2022 Jan; 386(1):11-23. PubMed ID: 34986284
[TBL] [Abstract][Full Text] [Related]
7. Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
Liu L; Lei M; Fu R; Han B; Zhao X; Liu R; Zhang Y; Jiao W; Miao M; Zhang F; Zhang L; Wu D
J Hematol Oncol; 2022 Aug; 15(1):105. PubMed ID: 35962406
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
Patel BA; Groarke EM; Lotter J; Shalhoub R; Gutierrez-Rodrigues F; Rios O; Quinones Raffo D; Wu CO; Young NS
Blood; 2022 Jan; 139(1):34-43. PubMed ID: 34525188
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study.
Fang M; Song H; Zhang J; Li S; Shen D; Tang Y
Pediatr Hematol Oncol; 2021 Oct; 38(7):633-646. PubMed ID: 33724146
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.
McQuilten Z; Heritier S; Fox L; Fox V; Young L; Blombery P; Cunningham I; Curnow J; Higgins A; Hiwase DK; Filshie R; Firkin F; Lacaze P; Mason K; Mills AK; Pepperell D; Patil S; Stevenson W; Szer J; Waters N; Wilson K; Ting S; Wood E
BMJ Open; 2024 Jan; 14(1):e076246. PubMed ID: 38238183
[TBL] [Abstract][Full Text] [Related]
11. Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag.
Li R; Zhou J; Liu Z; Chen X; Long Q; Yang Y; Lin S; Jia J; He G; Li J
Front Immunol; 2022; 13():884312. PubMed ID: 35720405
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
Hwang YY; Chan TSY; Chan FHY; Lau CWP; Luk YY; Lau GWN; Chan KP; Leung KH; Kho B; Lau JSM; Lau CK; Mak V; Yip SF; Lin SY; Sim JPY; Kwong YL
Ann Hematol; 2022 Jun; 101(6):1163-1172. PubMed ID: 35412083
[TBL] [Abstract][Full Text] [Related]
14. Effects and Predictive Factors of Immunosuppressive Therapy Combined with Umbilical Cord Blood Infusion in Patients with Severe Aplastic Anemia.
Zhang X; Li Z; Geng W; Song B; Wan C
Yonsei Med J; 2018 Jul; 59(5):643-651. PubMed ID: 29869462
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
Imada K; Obara N; Iida H; Imajo K; Maeda T; Usuki K; Fanghong Z; Hombo Y; Tajima T; Kumagai A; Matsuda A; Nakao S
Intern Med; 2021 Apr; 60(8):1159-1168. PubMed ID: 33229810
[TBL] [Abstract][Full Text] [Related]
16. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic choices in immune aplastic anemia.
Scheinberg P
F1000Res; 2020; 9():. PubMed ID: 32953089
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan.
Foucar CE; Foley DH; Aldous J; Burke PW; Pettit KR; Benitez LL; Perissinotti AJ; Marini BL; Boonstra P; Bixby DL
Eur J Haematol; 2024 Mar; 112(3):424-432. PubMed ID: 37929654
[TBL] [Abstract][Full Text] [Related]
19. Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review.
Yang Y; Ji J; Tang Z; Han B
Front Oncol; 2021; 11():614965. PubMed ID: 33981596
[No Abstract] [Full Text] [Related]
20. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):450-456. PubMed ID: 30504345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
